文献速递前列腺癌

非转移性前列腺癌男性其他原因死亡预测工具的本土化适配与国家验证

Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-01-03

基于美国退伍军人健康管理局2001至2018年确诊的非转移性前列腺癌男性观察队列,对VACS-CCI进行重新校准和验证以预测非前列腺癌死亡,并与前列腺癌死亡预测工具比较。VACS-CCI验证区分度C统计量0.75(95%CI 0.74-0.75),优于年龄和CCI单独的0.67(95%CI 0.67-0.68);前列腺癌死亡预测工具C统计量0.81(95%CI 0.78-0.83),两者校准良好。VACS-CCI已准备在VA内部实施,但需在VA外验证后方可外部应用。

要点

  • VACS-CCI预测非前列腺癌死亡的验证C统计量为0.75(95%CI 0.74-0.75)。
  • 年龄和CCI单独预测非前列腺癌死亡的C统计量为0.67(95%CI 0.67-0.68)。
  • 前列腺癌死亡预测工具验证C统计量为0.81(95%CI 0.78-0.83)。

核心结论

  • VACS-CCI已准备在退伍军人健康管理局内部实施。
  • 电子健康记录辅助计算可行,较年龄和CCI单独提高准确性,并可能减轻提供者估计中的不准确和偏倚。

研究设计与样本

  • 观察性队列,纳入2001至2018年美国退伍军人健康管理局全国活检确诊的非转移性前列腺癌男性,按诊断年份分为开发集(2001-2006年和2008-2018年)和验证集(2007年)。
  • 共107370人,观察到24977例死亡,其中86%为非前列腺癌死亡;中位年龄65岁,4947人为黑人,5010人为西班牙裔。

主要发现

  • VACS-CCI预测非前列腺癌死亡的验证C统计量为0.75(95%CI 0.74-0.75)。
  • 年龄和CCI单独预测非前列腺癌死亡的C统计量为0.67(95%CI 0.67-0.68)。
  • 前列腺癌死亡预测工具验证C统计量为0.81(95%CI 0.78-0.83)。
  • 两种工具总体及各亚组内校准良好。

关键数值与推荐

  • VACS-CCI预测非前列腺癌死亡的验证C统计量为0.75(95%CI 0.74-0.75)。
  • 年龄和CCI单独预测非前列腺癌死亡的C统计量为0.67(95%CI 0.67-0.68)。
  • 前列腺癌死亡预测工具验证C统计量为0.81(95%CI 0.78-0.83)。

临床怎么用

  • VACS-CCI已准备在退伍军人健康管理局内部实施。
  • 电子健康记录辅助计算可行,可较年龄和CCI单独提高准确性,并可能减轻提供者估计中的不准确和偏倚。
  • VACS-CCI应在退伍军人健康管理局外部验证后方可外部应用。

局限性

  • 因数据缺失,18009/125379(14%)被排除。
  • VACS-CCI应在退伍军人健康管理局外部验证后方可外部应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An electronic health record-based tool could improve accuracy and eliminate bias in provider estimation of the risk of death from other causes among men with nonmetastatic cancer. OBJECTIVE: To recalibrate and validate the Veterans Aging Cohort Study Charlson Comorbidity Index (VACS-CCI) to predict non-prostate cancer mortality (non-PCM) and to compare it with a tool predicting prostate cancer mortality (PCM). DESIGN, SETTING, AND PARTICIPANTS: An observational cohort of men with biopsy-confirmed nonmetastatic prostate cancer, enrolled from 2001 to 2018 in the national US Veterans Health Administration (VA), was divided by the year of diagnosis into the development (2001-2006 and 2008-2018) and validation (2007) sets. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Mortality (all cause, non-PCM, and PCM) was evaluated. Accuracy was assessed using calibration curves and C statistic in the development, validation, and combined sets; overall; and by age (<65 and 65+ yr), race (White and Black), Hispanic ethnicity, and treatment groups. RESULTS AND LIMITATIONS: Among 107 370 individuals, we observed 24 977 deaths (86% non-PCM). The median age was 65 yr, 4947 were Black, and 5010 were Hispanic. Compared with CCI and age alone (C statistic 0.67, 95% confidence interval [CI] 0.67-0.68), VACS-CCI demonstrated improved validated discrimination (C statistic 0.75, 95% CI 0.74-0.75 for non-PCM). The prostate cancer mortality tool also discriminated well in validation (C statistic 0.81, 95% CI 0.78-0.83). Both were well calibrated overall and within subgroups. Owing to missing data, 18 009/125 379 (14%) were excluded, and VACS-CCI should be validated outside the VA prior to outside application. CONCLUSIONS: VACS-CCI is ready for implementation within the VA. Electronic health record-assisted calculation is feasible, improves accuracy over age and CCI alone, and could mitigate inaccuracy and bias in provider estimation. PATIENT SUMMARY: Veterans Aging Cohort Study Charlson Comorbidity Index is ready for application within the Veterans Health Administration. Electronic health record-assisted calculation is feasible, improves accuracy over age and Charlson Comorbidity Index alone, and might help mitigate inaccuracy and bias in provider estimation of the risk of non-prostate cancer mortality.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Justice AC, Tate JP, Howland F, et al. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38171965. doi:10.1016/j.euo.2023.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。